CA1205399A - Anticorps contre l'interferon et method de production - Google Patents
Anticorps contre l'interferon et method de productionInfo
- Publication number
- CA1205399A CA1205399A CA000448830A CA448830A CA1205399A CA 1205399 A CA1205399 A CA 1205399A CA 000448830 A CA000448830 A CA 000448830A CA 448830 A CA448830 A CA 448830A CA 1205399 A CA1205399 A CA 1205399A
- Authority
- CA
- Canada
- Prior art keywords
- interferon
- protein
- daltons
- human
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 508
- 108010050904 Interferons Proteins 0.000 title claims abstract description 508
- 238000000034 method Methods 0.000 title claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 293
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 293
- 241000282414 Homo sapiens Species 0.000 claims abstract description 237
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 22
- 230000003053 immunization Effects 0.000 claims abstract description 20
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 18
- 230000001900 immune effect Effects 0.000 claims abstract description 14
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 229940079322 interferon Drugs 0.000 claims description 369
- 235000018102 proteins Nutrition 0.000 claims description 226
- 230000000694 effects Effects 0.000 claims description 161
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 100
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 100
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 100
- 230000001064 anti-interferon Effects 0.000 claims description 87
- 230000000840 anti-viral effect Effects 0.000 claims description 71
- 229920002401 polyacrylamide Polymers 0.000 claims description 65
- 108060003951 Immunoglobulin Proteins 0.000 claims description 52
- 102000018358 immunoglobulin Human genes 0.000 claims description 52
- 229940072221 immunoglobulins Drugs 0.000 claims description 49
- 238000010186 staining Methods 0.000 claims description 48
- 239000011159 matrix material Substances 0.000 claims description 45
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 31
- 229940117913 acrylamide Drugs 0.000 claims description 31
- 229920000936 Agarose Polymers 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 19
- 238000009739 binding Methods 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 230000000052 comparative effect Effects 0.000 claims description 14
- 235000004252 protein component Nutrition 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000002797 proteolythic effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004593 Epoxy Substances 0.000 claims description 11
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 10
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 10
- 239000002532 enzyme inhibitor Substances 0.000 claims description 10
- 239000002753 trypsin inhibitor Substances 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 9
- 102000001399 Kallikrein Human genes 0.000 claims description 6
- 108060005987 Kallikrein Proteins 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 230000000937 inactivator Effects 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 229940070376 protein Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 70
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 108010047761 Interferon-alpha Proteins 0.000 description 55
- 102000006992 Interferon-alpha Human genes 0.000 description 55
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 53
- 238000002360 preparation method Methods 0.000 description 51
- 239000000243 solution Substances 0.000 description 48
- 241000894007 species Species 0.000 description 47
- 238000001042 affinity chromatography Methods 0.000 description 43
- 229920002684 Sepharose Polymers 0.000 description 36
- 238000000746 purification Methods 0.000 description 33
- 239000011780 sodium chloride Substances 0.000 description 29
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 22
- 239000003446 ligand Substances 0.000 description 21
- 229920002307 Dextran Polymers 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 238000010828 elution Methods 0.000 description 19
- 239000012535 impurity Substances 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 18
- 229940047124 interferons Drugs 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000008363 phosphate buffer Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 239000000306 component Substances 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000009102 absorption Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 244000005700 microbiome Species 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002022 anti-cellular effect Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012160 loading buffer Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 description 7
- 102100039729 Interferon alpha-21 Human genes 0.000 description 7
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 239000011544 gradient gel Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000220317 Rosa Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000002799 interferon inducing agent Substances 0.000 description 3
- -1 pH 7.2 Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012504 chromatography matrix Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- 241001505295 Eros Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000684181 Homo sapiens Selenoprotein P Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100496087 Mus musculus Clec12a gene Proteins 0.000 description 1
- 101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 102100023843 Selenoprotein P Human genes 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 244000166071 Shorea robusta Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- XMBWDFGMSWQBCA-CONNIKPHSA-N iodane Chemical compound [135IH] XMBWDFGMSWQBCA-CONNIKPHSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108700006586 polylysine-agarose Proteins 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940119265 sepp Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000448830A CA1205399A (fr) | 1979-04-20 | 1984-03-05 | Anticorps contre l'interferon et method de production |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK164579 | 1979-04-20 | ||
| DK79180 | 1980-02-22 | ||
| DK1645/79 | 1980-04-02 | ||
| DK791/80 | 1980-04-02 | ||
| DK1484/80 | 1980-04-02 | ||
| DK148480 | 1980-04-02 | ||
| CA000350293A CA1168151A (fr) | 1979-04-20 | 1980-04-21 | Interferon et methode de production |
| CA000448830A CA1205399A (fr) | 1979-04-20 | 1984-03-05 | Anticorps contre l'interferon et method de production |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000350293A Division CA1168151A (fr) | 1979-04-20 | 1980-04-21 | Interferon et methode de production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1205399A true CA1205399A (fr) | 1986-06-03 |
Family
ID=27426235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000448830A Expired CA1205399A (fr) | 1979-04-20 | 1984-03-05 | Anticorps contre l'interferon et method de production |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1205399A (fr) |
-
1984
- 1984-03-05 CA CA000448830A patent/CA1205399A/fr not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0091543B1 (fr) | Anticorps anti-interféron et leur procédé de préparation | |
| Langbeheim et al. | Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. | |
| Akita et al. | Comparison of four purification methods for the production of immunoglobulins from eggs laid by hens immunized with an enterotoxigenic E. coli strain | |
| KR910006602B1 (ko) | 면역 인터페론의 제조방법 | |
| Rose et al. | Purification and chemical characterization of a cholera toxin-cross-reactive cytolytic enterotoxin produced by a human isolate of Aeromonas hydrophila | |
| US4681930A (en) | Immune interferon and a method for its extraction and purification | |
| US4902618A (en) | Production of hybridoma antibodies for interferon | |
| US4604284A (en) | Homogeneous immune interferon fragment | |
| US6117423A (en) | Highly purified species of human leukocyte interferon | |
| KR0180527B1 (ko) | 보르데텔라 퍼투스시스로부터 69000달톤의 항원성 단백질을 추출 및 정제하는 방법 | |
| Le et al. | Monoclonal antibodies to human immune interferon and their application for affinity chromatography | |
| Berg | Sequential antibody affinity chromatography of human leukocyte interferon | |
| US4617378A (en) | Purification of biologically active human immune interferon | |
| CA1205399A (fr) | Anticorps contre l'interferon et method de production | |
| Berg | Identification, production, and characterization of murine monoclonal antibody (LO-22) recognizing 12 native species of human alpha interferon | |
| Zheng et al. | An antigen-specific helper T cell hybridoma produces an antigen-specific suppressor inducer molecule with identical antigenic fine specificity. Implications for the antigen recognition and function of helper and suppressor inducer T cells. | |
| EP0152346A2 (fr) | Procédé de purification de gamma-interféron | |
| WO1983000693A1 (fr) | SUJETS CONCERNANT DES PROTEINES DU SOUS-TYPE DE L'INTERFERON 'alpha' HUMAIN ET ANTICORPS CORRESPONDANTS | |
| FI79121B (fi) | Antikroppar mot le-formiga maenniskointerferonproteiners immunologiska determinanter och foerfarande foer producering av dessa antikroppan. | |
| IE55792B1 (en) | Anti-interferon antibodies and method of producing same | |
| Salvarelli et al. | Purification and Characterization of a Ribonuclease from Aspergillus giganteus IFO 5818, the Gigantin: Immunological and Enzymic Comparison with Alphasarcin | |
| Manderino et al. | Purification of human C5a des arg by immunoadsorbent and molecular sieve chromatography | |
| Santucci et al. | HPLC immunoaffinity purification of rabies virus glycoprotein using immobilized antipeptide antibodies | |
| Vosti et al. | Extraction of streptococcal type 12 M protein by cyanogen bromide | |
| JP3158254B2 (ja) | インターフェロン精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |